Mitsubishi Tanabe Pharma America

Neuroscience Parkinson's disease
#Mitsubishi Tanabe Pharma America #Neurodegenerative disorders #NeuroDerm #Parkinson's #Phase III trial

Data support one-year efficacy of ND0612 in Parkinson’s disease

New data from the Phase III BouNDless trial and its ongoing open-label extension (OLE) support the long-term efficacy of ND0612 in people with Parkinson’s disease (PD) experiencing motor fluctuations. The new clinical trial data was shared at the 2024 International Congress of Parkinson’s Disease and Movement… Read More

#News